Skip to main content

Advertisement

SpringerLink
Log in

Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Porphobilinogen deaminase (PBGD), the third enzyme in the biosynthesis of heme, is deficient in acute intermittent porphyria (AIP). AIP is a genetic disease characterized by neurovisceral and psychiatric disturbances. Despite a palliative treatment, it may still be lethal. An initial step towards gene therapy was recently taken by showing that PBGD could be expressed to correct the enzyme deficiency in AIP fibroblasts. The aim of the present study was to investigate whether the biochemical defect can be corrected by using non-viral gene delivery. The biochemical defect in human and mouse PBGD deficient fibroblasts was demonstrated by analyzing synthesis of the heme precursor, protoporphyrin (PP), after addition of 5-aminolevulinic acid (ALA). Human AIP fibroblasts synthesized 21% and mouse PBGD deficient fibroblasts only 11% of the PP amount synthesized in respective control cells. Gene delivery increased the PBGD activity 88–200 fold in human AIP fibroblasts and synthesis of PP was increased from 21–152% of normal after ALA incubation. Similar results were obtained in mouse PBGD deficient cells, although the PP levels were several-fold lower as compared to human cells. HPLC analysis confirmed that PP was the main porphyrin intermediate that was formed. Addition of porphobilinogen (PBG) resulted in 3–7 fold lower synthesis of PP as compared to ALA addition. These results show that non-viral gene delivery of plasmids encoding PBGD results in a high expression of functional PBGD shown by induced synthesis of PP in PBGD deficient cells after supplementation of ALA and PBG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderson KE, Sassa S, Bishop DF, Desnick RJ: Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: C.R. Scriver, A.L. Beaudet, D. Valle, W.S. Sly (eds). The Metabolic and Molecular Bases of Inherited Disease, Vol. 2, 8th edn. New York: McGraw-Hill, 2001, pp 2991-3062

    Google Scholar 

  2. Johansson A, Möller C, Gellerfors P, Harper P: Non-viral mediated gene transfer of porphobilinogen deaminase into mammalian cells. Scand J Clin Lab Invest 62: 105-114, 2002

    Google Scholar 

  3. Sassa S, Solish G, Levere RD, Kappas A: Studies in porphyria IV Expression of the gene defect of acute intermittent porphyria in cultured human skin fibroblasts and amniotic cells: Prenatal diagnosis of the porphyric trait. J Exp Med 142: 722-731, 1975

    Google Scholar 

  4. Granick S: The induction in vitro of the synthesis of delta-amino-levulinic acid synthetase in chemical porphyria: A response to certain drugs, sex hormones, and foreign chemicals. J Biol Chem 241: 1359-1375, 1966

    Google Scholar 

  5. Doss M: Relationships between acute hepatic porphyrias due to genetic variability of primary enzyme defects and limiting function of uro-porphyrinogen synthase. Int J Biochem 9: 911-916, 1978

    Google Scholar 

  6. Brodie MJ, Moore MR, Thompson GG, Campbell BC, Goldberg A: Is porphobilinogen deaminase activity a secondary control mechanism in haem biosynthesis in humans? Biochem Soc Transact 5: 1466-1468, 1977

    Google Scholar 

  7. Grandchamp B, De Verneuil H, Beaumont C, Chretien S, Walter O, Nordmann Y: Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene. Eur J Biochem 162: 105-110, 1987

    Google Scholar 

  8. Chretien S, Dubart A, Beaupain D, Raich N, Grandchamp B, Rosa J, Goossens M, Romeo PH: Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sci USA 85: 6-10, 1988

    Google Scholar 

  9. Gederaas OA, Berg K, Romslo I: A comparative study of normal and reverse phase high pressure liquid chromatography for analysis of porphyrins accumulated after 5-aminolaevulinic acid treatment of colon adenocarcinoma cells. Cancer Lett 150: 205-213, 2000

    Google Scholar 

  10. Lang K, Bolsen K, Stahl W, Ruzicka T, Sies H, Lehmann P, Fritsch C: The 5-aminolevulinic acid-induced porphyrin biosynthesis in benign and malignant cells of the skin. J Photochem Photobiol B 65: 29-34, 2001

    Google Scholar 

  11. Lindberg RL, Porcher C, Grandchamp B, Ledermann B, Burki K, Brandner S, Aguzzi A, Meyer UA: Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet 12: 195-199, 1996

    Google Scholar 

  12. Magnussen CR, Levine JB, Doherty JM, Cheesman JO, Tschudy DP: A red cell enzyme method for the diagnosis of acute intermittent porphyria. Blood 44: 857-868, 1974

    Google Scholar 

  13. Grandchamp B, Deybach JC, Grelier M, de Verneuil H, Nordmann Y: Studies of porphyrin synthesis in fibroblasts of patients with congenital erythropoietic porphyria and one patient with homozygous coproporphyria. Biochim Biophys Acta 629: 577-586, 1980

    Google Scholar 

  14. Sassa S, Schwartz S, Ruth G: Accumulation of protoporphyrin IX from delta-aminolevulinic acid in bovine skin fibroblasts with hereditary erythropoietic protoporphyria. A gene-dosage effect. J Exp Med 153: 1094-1101, 1981

    Google Scholar 

  15. Magness ST, Brenner DA: Ferrochelatase cDNA delivered by adenoviral vector corrects biochemical defect in protoporphyric cells. Hum Gene Ther 6: 1285-1290, 1995

    Google Scholar 

  16. Bloomer JR, Brenner DA, Mahoney MJ: Study of factors causing excess protoporphyrin accumulation in cultured skin fibroblasts from patients with protoporphyria. J Clin Invest 60: 1354-1361, 1977

    Google Scholar 

  17. Berg K, Anholt H, Bech O, Moan J: The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br J Cancer 74: 688-697, 1996

    Google Scholar 

  18. Hilf R, Havens JJ, Gibson SL: Effect of delta-aminolevulinic acid on protoporphyrin IX accumulation in tumor cells transfected with plasmids containing porphobilinogen deaminase DNA. Photochem Photobiol 70: 334-340, 1999

    Google Scholar 

  19. Russell VA, Lamm MCL, Taljaard JJF: Effects of delta-aminolaevulinic acid, porphobilinogen and structurally related amino acids on 2-deoxyglucose uptake in cultured neurons. Neurochem Res 7: 1009-1022, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Porphyria Centre Sweden, Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden

    Annika Johansson & Pauline Harper

  2. HemeBiotech A/S, idingö, Sweden

    Christer Möller

Authors
  1. Annika Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christer Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pauline Harper
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johansson, A., Möller, C. & Harper, P. Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery. Mol Cell Biochem 250, 65–71 (2003). https://doi.org/10.1023/A:1024946216776

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024946216776

Search

Navigation